Samantha J. Bents
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samantha J. Bents has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Cécile Viboud
Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
6 shared publications - Amanda C. Perofsky
Brotman Baty Institute for Precision Medicine Seattle Washington USA
5 shared publications - Audrie Lin
Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, Santa Cruz, CA, USA
3 shared publications - Benjamin F. Arnold
Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA
3 shared publications Chelsea Hansen
Fogarty International Center National Institutes of Health Bethesda MD USA
3 shared publications- Claire Perrin Smith
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, NC
3 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
Multi-model insights into racial and ethnic heterogeneities in early COVID-19 transmission and severity in the U.S.
The COVID-19 pandemic was marked by unequal disease burden across racial and ethnic groups in the US. Using a multi-model ensemble framework, we retrospectively assessed the impact of racial and ethnic heterogeneities in COVID-19 transmission and disease severity on mortality during the winter 2020–2021 surge in California and North Carolina. Models incorporating race and ethnicity projected mortality more accurately than null models, while the ensemble outperformed all individual models on average by weighted interval scores. Eliminating transmission heterogeneities produced larger mortality reductions than eliminating severity differences alone, particularly for Latino populations in California (55% reduction) and Black populations in North Carolina (28% reduction). Reducing severity heterogeneity also lowered mortality, with the greatest benefit among Black populations in both states (21% and 16% reductions in California and North Carolina, respectively). Eliminating both transmission and severity heterogeneity yielded the largest reductions overall, predicting 49–70% lower mortality across racial and ethnic groups in California and 23–40% in North Carolina. Mitigating transmission inequities also produced indirect benefits for non-targeted populations, highlighting the broad impact of reducing disparities in exposure risk and access to protective resources.
- 11 November 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
Open AccessMulti-model insights into racial and ethnic heterogeneities in early COVID-19 transmission and severity in the U.S.
The COVID-19 pandemic was marked by unequal disease burden across racial and ethnic groups in the US. Using a multi-model ensemble framework, we retrospectively assessed the impact of racial and ethnic heterogeneities in COVID-19 transmission and disease severity on mortality during the winter 2020–2021 surge in California and North Carolina. Models incorporating race and ethnicity projected mortality more accurately than null models, while the ensemble outperformed all individual models on average by weighted interval scores. Eliminating transmission heterogeneities produced larger mortality reductions than eliminating severity differences alone, particularly for Latino populations in California (55% reduction) and Black populations in North Carolina (28% reduction). Reducing severity heterogeneity also lowered mortality, with the greatest benefit among Black populations in both states (21% and 16% reductions in California and North Carolina, respectively). Eliminating both transmission and severity heterogeneity yielded the largest reductions overall, predicting 49–70% lower mortality across racial and ethnic groups in California and 23–40% in North Carolina. Mitigating transmission inequities also produced indirect benefits for non-targeted populations, highlighting the broad impact of reducing disparities in exposure risk and access to protective resources.
- Open Access
Effects of water quality, sanitation, handwashing and nutritional interventions on enteric pathogen seroconversion in rural Kenya: a cluster randomised trial
/Summary: Background: We evaluated whether water, sanitation, and handwashing (WASH) and nutrition interventions reduced enteric pathogen seroprevalence during the first two years of life among children in rural Kenya. Methods: We analysed the 2×2 factorial subset of the WASH Benefits Kenya cluster-randomised trial (control, WASH, nutrition, and WASH plus nutrition). Dried blood spots were collected from all children in the birth cohort after two years of intervention and at 6 and 12 months within a longitudinal substudy. Immunoglobulin G (IgG) responses were measured using a multiplex bead assay that included 12 pathogens. The primary outcome was IgG seroprevalence at 2 years. We estimated intention-to-treat differences, comparing WASH with no WASH and nutrition with no nutrition across the factorial design. Trial registration: NCT01704105 . Findings: The primary analysis included 3030 children in 384 clusters (median age 23 months). Seroprevalence increased rapidly with age and exceeded 90% for norovirus, Campylobacter , and LT-ETEC by the final visit, with several pathogens at moderate prevalences (24% were seropositive to typhoidal S. enterica HlyE). Differences between intervention groups were small: lower T. solium (−3.3 percentage points [95% CI −6.3 to −0.2]) and higher E. histolytica (3.2 [0.1 to 6.3]) with WASH versus control, and lower V. cholerae (−1.1 [−1.8 to −0.3]) and Shigella /EIEC (−2.7 [−5.5 to 0.0]) with nutrition versus no nutrition. No comparison met the 5% Benjamini– Hochberg false discovery rate threshold. Secondary analyses and age-seroprevalence curves suggested modest reductions for some pathogens but increased norovirus seroprevalence around 12 months, when intervention adherence was highest. Interpretation: At achieved adherence levels, household-level WASH and nutrition interventions were insufficient to reduce widespread early-life enteric pathogen exposure in this high-transmission setting, supporting the development of complementary vaccine and transmission-control strategies. Funding: National Institutes of Health (R01AI166671, R01AI106878, R01AI134814). The original WASH Benefits trial was funded by the Gates Foundation (OPPGD759).
Open AccessEffects of water quality, sanitation, handwashing and nutritional interventions on enteric pathogen seroconversion in rural Kenya: a cluster randomised trial
/Summary: Background: We evaluated whether water, sanitation, and handwashing (WASH) and nutrition interventions reduced enteric pathogen seroprevalence during the first two years of life among children in rural Kenya. Methods: We analysed the 2×2 factorial subset of the WASH Benefits Kenya cluster-randomised trial (control, WASH, nutrition, and WASH plus nutrition). Dried blood spots were collected from all children in the birth cohort after two years of intervention and at 6 and 12 months within a longitudinal substudy. Immunoglobulin G (IgG) responses were measured using a multiplex bead assay that included 12 pathogens. The primary outcome was IgG seroprevalence at 2 years. We estimated intention-to-treat differences, comparing WASH with no WASH and nutrition with no nutrition across the factorial design. Trial registration: NCT01704105 . Findings: The primary analysis included 3030 children in 384 clusters (median age 23 months). Seroprevalence increased rapidly with age and exceeded 90% for norovirus, Campylobacter , and LT-ETEC by the final visit, with several pathogens at moderate prevalences (24% were seropositive to typhoidal S. enterica HlyE). Differences between intervention groups were small: lower T. solium (−3.3 percentage points [95% CI −6.3 to −0.2]) and higher E. histolytica (3.2 [0.1 to 6.3]) with WASH versus control, and lower V. cholerae (−1.1 [−1.8 to −0.3]) and Shigella /EIEC (−2.7 [−5.5 to 0.0]) with nutrition versus no nutrition. No comparison met the 5% Benjamini– Hochberg false discovery rate threshold. Secondary analyses and age-seroprevalence curves suggested modest reductions for some pathogens but increased norovirus seroprevalence around 12 months, when intervention adherence was highest. Interpretation: At achieved adherence levels, household-level WASH and nutrition interventions were insufficient to reduce widespread early-life enteric pathogen exposure in this high-transmission setting, supporting the development of complementary vaccine and transmission-control strategies. Funding: National Institutes of Health (R01AI166671, R01AI106878, R01AI134814). The original WASH Benefits trial was funded by the Gates Foundation (OPPGD759).
- Open Access
Effects of water quality, sanitation, handwashing and nutritional interventions on enteric pathogen seroconversion in rural Bangladesh: a cluster randomised trial
/Summary: Background: Improvements to water quality, sanitation, handwashing (WASH) and nutrition may prevent enteric pathogen infection during the first two years of life. Few randomised controlled trials have measured pathogen-specific effects of WASH and nutritional interventions. Methods: Within a 2×2 factorial cluster-randomized trial of WASH and nutritional interventions in Bangladesh, we tested dried blood spot specimens with multiplex assay for IgG responses to 12 enteric pathogens: Norovirus , Campylobacter , LT-producing enterotoxigenic E. coli (LT-ETEC), Shigella , non-typhoidal and typhoidal Salmonella enterica , Vibrio cholerae , Cryptosporidium , Giardia , Entamoeba histolytica , Taenia solium , and Strongyloides stercoralis . Primary analysis included children with IgG measurements at ∼24 months, and secondary analysis assessed early effects in a sub-study at ∼14 months. We estimated age-specific seroprevalence and marginal seroprevalence differences for WASH and nutrition effects. Trial is registered with ClinicalTrials.gov ( NCT01590095 ). Findings: Across the four arms (450 clusters), 4817 samples were tested for IgG responses, 2453 samples at the primary endpoint. Seroprevalence increased with age, consistent with intense early-life transmission. For highest transmission pathogens, >94% of children had seroconverted to norovirus , LT-ETEC and Campylobacter by 12-18 months. WASH effects were modest and pathogen-specific but generally protective. At 24 months, children that received WASH interventions had less antibody against Shigella (–4.5%, 95% CI –7.6% to –1.5%), non-typhoidal S. enterica (–4.0%, 95% CI –6.5% to –1.5%), and Giardia (–3.4%, 95% CI –6.7% to –0.2%), although not after multiple-testing correction. Nutrition had limited effects on most enteric pathogens, but reduced non-typhoidal S. enterica at 14 months (–6.4%, 95% CI: –9.8% to –3.0%). Interpretation: Multiplex serology provided evidence that WASH may modestly reduce cumulative exposure to selected enteric pathogens, but household-level interventions were insufficient to substantially disrupt transmission in this high-exposure setting. Funding: National Institutes of Health (R01AI166671, R01AI106878, R01AI134814). The original WASH Benefits trial was funded by Gates Foundation (OPPGD759).
Open AccessEffects of water quality, sanitation, handwashing and nutritional interventions on enteric pathogen seroconversion in rural Bangladesh: a cluster randomised trial
/Summary: Background: Improvements to water quality, sanitation, handwashing (WASH) and nutrition may prevent enteric pathogen infection during the first two years of life. Few randomised controlled trials have measured pathogen-specific effects of WASH and nutritional interventions. Methods: Within a 2×2 factorial cluster-randomized trial of WASH and nutritional interventions in Bangladesh, we tested dried blood spot specimens with multiplex assay for IgG responses to 12 enteric pathogens: Norovirus , Campylobacter , LT-producing enterotoxigenic E. coli (LT-ETEC), Shigella , non-typhoidal and typhoidal Salmonella enterica , Vibrio cholerae , Cryptosporidium , Giardia , Entamoeba histolytica , Taenia solium , and Strongyloides stercoralis . Primary analysis included children with IgG measurements at ∼24 months, and secondary analysis assessed early effects in a sub-study at ∼14 months. We estimated age-specific seroprevalence and marginal seroprevalence differences for WASH and nutrition effects. Trial is registered with ClinicalTrials.gov ( NCT01590095 ). Findings: Across the four arms (450 clusters), 4817 samples were tested for IgG responses, 2453 samples at the primary endpoint. Seroprevalence increased with age, consistent with intense early-life transmission. For highest transmission pathogens, >94% of children had seroconverted to norovirus , LT-ETEC and Campylobacter by 12-18 months. WASH effects were modest and pathogen-specific but generally protective. At 24 months, children that received WASH interventions had less antibody against Shigella (–4.5%, 95% CI –7.6% to –1.5%), non-typhoidal S. enterica (–4.0%, 95% CI –6.5% to –1.5%), and Giardia (–3.4%, 95% CI –6.7% to –0.2%), although not after multiple-testing correction. Nutrition had limited effects on most enteric pathogens, but reduced non-typhoidal S. enterica at 14 months (–6.4%, 95% CI: –9.8% to –3.0%). Interpretation: Multiplex serology provided evidence that WASH may modestly reduce cumulative exposure to selected enteric pathogens, but household-level interventions were insufficient to substantially disrupt transmission in this high-exposure setting. Funding: National Institutes of Health (R01AI166671, R01AI106878, R01AI134814). The original WASH Benefits trial was funded by Gates Foundation (OPPGD759).
- Open Access
Rethinking seasonal COVID-19 vaccination in the endemic era: summer timing, eligibility, and frequency in the United States
Importance: With a recent shift towards summer seasonal predominance of COVID-19 across much of the US, debate continues over optimal COVID-19 vaccination strategies regarding timing (including summer vaccination), eligibility, and dosing frequency. We evaluated the population-level impact of alternative vaccine strategies to inform US and state vaccine policy. Objective: To compare reductions in COVID-19 hospitalizations under different vaccination timing, eligibility, and dosing frequency. Design: Decision analytical model using a stochastic individual-based model of SARS-CoV-2 transmission, calibrated to US COVID-19 hospitalization incidence from May 2024-April 2025. Setting: Simulated US national population, with additional scenarios representing state-level seasonal patterns. Participants: Simulated population of 5 million individuals with US age structure, stratified by risk group (immunocompetent, high risk with comorbid conditions, or immunocompromised). Exposures: Vaccination timing, universal or age- and risk-based eligibility, and dosing frequency, including a hybrid strategy of universal annual vaccination with a second dose for adults ≥65 years and immunocompromised adults (US vaccine policy during the study period). Main Outcomes and Measures: COVID-19 hospitalization risk per 100,000 persons by age-risk group, measured among vaccinated individuals and in the total population. Results: If summer COVID-19 vaccination timing is feasible, annual universal vaccination in July minimized risk (441 [95% UI: 423-463] COVID-19 hospitalizations per 100,000 persons among adults ≥65 years) compared to a counterfactual scenario with no additional vaccination given during the study period (578 [553-601]). If timing does not change, hybrid vaccination minimized risk, followed by semiannual risk-based vaccination (460 [440-487] and 477 [454-499] hospitalizations per 100,000 in adults ≥65 years, respectively). The advantage of summer timing diminished if vaccine coverage decreased by 5-10 absolute percentage points (25-50% relative decrease). The magnitude of benefit from summer-timed vaccination and semiannual doses in the highest-risk groups varied regionally. Conclusions and Relevance: Although annual COVID-19 vaccination has historically been timed for winter transmission, summer vaccination may avert more hospitalizations if coverage is maintained, especially in states with predominantly summer transmission including Western and Southern states. The comparative impact of vaccination strategies, especially the benefit of a semiannual dose in the highest-risk groups, may vary regionally. COVID-19 vaccination timing and eligibility may warrant reconsideration. Key points: Question: Given increasing summer predominance of COVID-19 in the US, can changing the timing, eligibility, or dosing frequency of vaccination further reduce hospitalizations? Findings: In a decision analytical model calibrated to US COVID-19 hospitalization incidence, annual universal vaccination in July reduced hospitalization risk in adults ≥65 years more than recently recommended hybrid vaccination (universal vaccination with a second dose in the highest-risk groups) with historical fall timing, provided historical vaccine coverage was maintained. The benefit from summer-timed and semiannual vaccination in the highest-risk groups varied regionally. Meaning: Shifting COVID-19 vaccination to summer could further reduce hospitalizations, if coverage is maintained.
Open AccessRethinking seasonal COVID-19 vaccination in the endemic era: summer timing, eligibility, and frequency in the United States
Importance: With a recent shift towards summer seasonal predominance of COVID-19 across much of the US, debate continues over optimal COVID-19 vaccination strategies regarding timing (including summer vaccination), eligibility, and dosing frequency. We evaluated the population-level impact of alternative vaccine strategies to inform US and state vaccine policy. Objective: To compare reductions in COVID-19 hospitalizations under different vaccination timing, eligibility, and dosing frequency. Design: Decision analytical model using a stochastic individual-based model of SARS-CoV-2 transmission, calibrated to US COVID-19 hospitalization incidence from May 2024-April 2025. Setting: Simulated US national population, with additional scenarios representing state-level seasonal patterns. Participants: Simulated population of 5 million individuals with US age structure, stratified by risk group (immunocompetent, high risk with comorbid conditions, or immunocompromised). Exposures: Vaccination timing, universal or age- and risk-based eligibility, and dosing frequency, including a hybrid strategy of universal annual vaccination with a second dose for adults ≥65 years and immunocompromised adults (US vaccine policy during the study period). Main Outcomes and Measures: COVID-19 hospitalization risk per 100,000 persons by age-risk group, measured among vaccinated individuals and in the total population. Results: If summer COVID-19 vaccination timing is feasible, annual universal vaccination in July minimized risk (441 [95% UI: 423-463] COVID-19 hospitalizations per 100,000 persons among adults ≥65 years) compared to a counterfactual scenario with no additional vaccination given during the study period (578 [553-601]). If timing does not change, hybrid vaccination minimized risk, followed by semiannual risk-based vaccination (460 [440-487] and 477 [454-499] hospitalizations per 100,000 in adults ≥65 years, respectively). The advantage of summer timing diminished if vaccine coverage decreased by 5-10 absolute percentage points (25-50% relative decrease). The magnitude of benefit from summer-timed vaccination and semiannual doses in the highest-risk groups varied regionally. Conclusions and Relevance: Although annual COVID-19 vaccination has historically been timed for winter transmission, summer vaccination may avert more hospitalizations if coverage is maintained, especially in states with predominantly summer transmission including Western and Southern states. The comparative impact of vaccination strategies, especially the benefit of a semiannual dose in the highest-risk groups, may vary regionally. COVID-19 vaccination timing and eligibility may warrant reconsideration. Key points: Question: Given increasing summer predominance of COVID-19 in the US, can changing the timing, eligibility, or dosing frequency of vaccination further reduce hospitalizations? Findings: In a decision analytical model calibrated to US COVID-19 hospitalization incidence, annual universal vaccination in July reduced hospitalization risk in adults ≥65 years more than recently recommended hybrid vaccination (universal vaccination with a second dose in the highest-risk groups) with historical fall timing, provided historical vaccine coverage was maintained. The benefit from summer-timed and semiannual vaccination in the highest-risk groups varied regionally. Meaning: Shifting COVID-19 vaccination to summer could further reduce hospitalizations, if coverage is maintained.
- Open Access
Adaptive multi-model ensembles for improved epidemic projections and decision support
In recent years, the use of multi-model ensemble projections in infectious disease modeling has become an established methodological approach to account for and integrate across uncertainties and structural differences present in individual models. However, the creation of long-term ensemble projections through these coordinated efforts is resource-intensive, demanding the input of multiple research teams and substantial computational power. This typically limits the ability to refine projections, update the selection of plausible epidemic trajectories, or expand the number of scenarios that can be assessed, even as new empirical data become available. To address this challenge, we define an adaptive ensemble approach that, analogously to a multi-model particle filtering method, dynamically selects individual model trajectories based on observed data throughout the epidemic projection period. We demonstrate the effectiveness of this methodology using the U.S. Flu Scenario Modeling Hub (SMH) projections for influenza hospitalizations in the United States during the 2023-2024 and 2024-2025 winter seasons. Our findings show that the adaptive ensemble yields improved predictive accuracy with respect to the original SMH ensemble projections across several scoring rules and geographical resolutions. Furthermore, the adaptive ensemble approach offers two additional applications: i) the dynamic assignment of posterior probabilities to epidemic scenarios, identifying the most plausible scenario, and representing how reality is captured by a combination of scenarios, and ii) the potential use for short-term forecasting. The adaptive ensemble approach is able to identify the most likely scenarios for the 2023-2024 and 2024-2025 U.S. influenza seasons, even in the early stages of the epidemic. It outperforms, retrospectively, a baseline model in short-term forecasting of influenza hospitalizations in the United States during the two seasons across various horizons and scoring rules, showing potential to contribute to real-time collaborative forecasting challenges such as CDC’s FluSight. The proposed approach offers an efficient or low-resource strategy to increase the impact of multi-model epidemic projections by providing real-time support to modeling teams, public health authorities, and decision-makers.
Open AccessAdaptive multi-model ensembles for improved epidemic projections and decision support
In recent years, the use of multi-model ensemble projections in infectious disease modeling has become an established methodological approach to account for and integrate across uncertainties and structural differences present in individual models. However, the creation of long-term ensemble projections through these coordinated efforts is resource-intensive, demanding the input of multiple research teams and substantial computational power. This typically limits the ability to refine projections, update the selection of plausible epidemic trajectories, or expand the number of scenarios that can be assessed, even as new empirical data become available. To address this challenge, we define an adaptive ensemble approach that, analogously to a multi-model particle filtering method, dynamically selects individual model trajectories based on observed data throughout the epidemic projection period. We demonstrate the effectiveness of this methodology using the U.S. Flu Scenario Modeling Hub (SMH) projections for influenza hospitalizations in the United States during the 2023-2024 and 2024-2025 winter seasons. Our findings show that the adaptive ensemble yields improved predictive accuracy with respect to the original SMH ensemble projections across several scoring rules and geographical resolutions. Furthermore, the adaptive ensemble approach offers two additional applications: i) the dynamic assignment of posterior probabilities to epidemic scenarios, identifying the most plausible scenario, and representing how reality is captured by a combination of scenarios, and ii) the potential use for short-term forecasting. The adaptive ensemble approach is able to identify the most likely scenarios for the 2023-2024 and 2024-2025 U.S. influenza seasons, even in the early stages of the epidemic. It outperforms, retrospectively, a baseline model in short-term forecasting of influenza hospitalizations in the United States during the two seasons across various horizons and scoring rules, showing potential to contribute to real-time collaborative forecasting challenges such as CDC’s FluSight. The proposed approach offers an efficient or low-resource strategy to increase the impact of multi-model epidemic projections by providing real-time support to modeling teams, public health authorities, and decision-makers.
- Open Access
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11015
Multiplex serology reveals age-specific immunodynamics of respiratory pathogens in the wake of the COVID-19 pandemic
The rebound of endemic respiratory viruses following the COVID-19 pandemic was marked by atypical transmission dynamics, with children experiencing increased disease burden and out-of-season epidemics as restrictions relaxed. Here we used serology from a newly developed quantitative multiplex assay to assess the post-pandemic immunity debt. We assessed age-specific antibody dynamics across a broad range of respiratory viruses, including influenza, respiratory syncytial virus, seasonal coronaviruses, and SARS-CoV-2 using serology collected in King County, Washington, US, from 2020-2022 (n = 1508). We found that respiratory virus immunodynamics differed between individuals <5 years of age and older individuals, with young children experiencing larger boosts and quicker waning of antibodies across pathogens. We confirmed that these patterns are upheld in a non-pandemic setting by analyzing influenza serology collected in South Africa between 2016-2018 (n = 1028). We incorporated our serological insights into an influenza transmission model calibrated to epidemiological data from King County and show that consideration of age-specific immunodynamics may be important to anticipate the effects of pandemic perturbations.
- 10 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11015
Open AccessMultiplex serology reveals age-specific immunodynamics of respiratory pathogens in the wake of the COVID-19 pandemic
The rebound of endemic respiratory viruses following the COVID-19 pandemic was marked by atypical transmission dynamics, with children experiencing increased disease burden and out-of-season epidemics as restrictions relaxed. Here we used serology from a newly developed quantitative multiplex assay to assess the post-pandemic immunity debt. We assessed age-specific antibody dynamics across a broad range of respiratory viruses, including influenza, respiratory syncytial virus, seasonal coronaviruses, and SARS-CoV-2 using serology collected in King County, Washington, US, from 2020-2022 (n = 1508). We found that respiratory virus immunodynamics differed between individuals <5 years of age and older individuals, with young children experiencing larger boosts and quicker waning of antibodies across pathogens. We confirmed that these patterns are upheld in a non-pandemic setting by analyzing influenza serology collected in South Africa between 2016-2018 (n = 1028). We incorporated our serological insights into an influenza transmission model calibrated to epidemiological data from King County and show that consideration of age-specific immunodynamics may be important to anticipate the effects of pandemic perturbations.
- Open Access
A framework for guiding integrated disease control measures through multipathogen surveillance
Global health programs have traditionally focused on single diseases. There is potential for synergy through integrated intervention delivery, particularly in areas with overlapping geographic disease burden, but there is limited methodology developed to guide integration. Here, we propose a framework to translate multipathogen surveillance data into summary indices that can guide integrated program delivery to target multiple pathogens at once. We considered several measures of diversity to quantify multipathogen infection or undervaccination across three large-scale surveys: subregions in Bangladesh (90 clusters, n = 7,187) and Kenya (89 clusters, n = 9,077), and a national survey in Cambodia (100 clusters, n = 2,150). We found that strategies guided by a measure of diversity, Rao's quadratic index, consistently identified more efficient integrated strategies than other multipathogen indices across a range of intervention combinations. We then identified case studies in each setting that used immunization as the backbone for integration and found that incorporating information from co-occurring pathogens led to only modest reductions in efficiency for vaccine-preventable diseases, while affording potentially large gains for other pathogens. Compared with a strategy that prioritized a single vaccine-preventable disease, prioritization using a multipathogen index required targeting 4% (95% CI: 0-12%) fewer spatial clusters in Bangladesh to target four additional pathogens, 10% fewer clusters in Kenya (95% CI: 3-17%), and 11% (95% CI: 5-22%) fewer clusters in Cambodia to reach 80% of all potential intervention beneficiaries across diseases. In all settings, we observed geographic clustering of multiple pathogens, with moderate to high spatial autocorrelation in Bangladesh (Moran's I = 0.58), Kenya (I = 0.56), and Cambodia (I = 0.26), indicating potential for more efficient, spatially concentrated integrated interventions. We also found that a multipathogen index was significantly associated with a multidimensional poverty index in Bangladesh (Spearman's ρ = 0.25), Kenya (ρ = 0.51), and Cambodia (ρ= 0.59), suggesting that multipathogen-guided strategies may effectively target impoverished populations with the highest public health need. The framework provides a systematic approach to guide integrated program delivery, offering potential for greater efficiency in disease control.
Open AccessA framework for guiding integrated disease control measures through multipathogen surveillance
Global health programs have traditionally focused on single diseases. There is potential for synergy through integrated intervention delivery, particularly in areas with overlapping geographic disease burden, but there is limited methodology developed to guide integration. Here, we propose a framework to translate multipathogen surveillance data into summary indices that can guide integrated program delivery to target multiple pathogens at once. We considered several measures of diversity to quantify multipathogen infection or undervaccination across three large-scale surveys: subregions in Bangladesh (90 clusters, n = 7,187) and Kenya (89 clusters, n = 9,077), and a national survey in Cambodia (100 clusters, n = 2,150). We found that strategies guided by a measure of diversity, Rao's quadratic index, consistently identified more efficient integrated strategies than other multipathogen indices across a range of intervention combinations. We then identified case studies in each setting that used immunization as the backbone for integration and found that incorporating information from co-occurring pathogens led to only modest reductions in efficiency for vaccine-preventable diseases, while affording potentially large gains for other pathogens. Compared with a strategy that prioritized a single vaccine-preventable disease, prioritization using a multipathogen index required targeting 4% (95% CI: 0-12%) fewer spatial clusters in Bangladesh to target four additional pathogens, 10% fewer clusters in Kenya (95% CI: 3-17%), and 11% (95% CI: 5-22%) fewer clusters in Cambodia to reach 80% of all potential intervention beneficiaries across diseases. In all settings, we observed geographic clustering of multiple pathogens, with moderate to high spatial autocorrelation in Bangladesh (Moran's I = 0.58), Kenya (I = 0.56), and Cambodia (I = 0.26), indicating potential for more efficient, spatially concentrated integrated interventions. We also found that a multipathogen index was significantly associated with a multidimensional poverty index in Bangladesh (Spearman's ρ = 0.25), Kenya (ρ = 0.51), and Cambodia (ρ= 0.59), suggesting that multipathogen-guided strategies may effectively target impoverished populations with the highest public health need. The framework provides a systematic approach to guide integrated program delivery, offering potential for greater efficiency in disease control.
- Open Access
Multiplex serology reveals age-specific immunodynamics of endemic respiratory pathogens in the wake of the COVID-19 pandemic
The rebound of endemic respiratory viruses following the COVID-19 pandemic was marked by atypical transmission dynamics, with children experiencing increased disease burden and out-of-season epidemics as restrictions relaxed. Here we used serology from a newly developed quantitative multiplex assay to assess the post-pandemic immunity debt, a drop in immunity due to a lack of endemic virus circulation during COVID-19. We assessed age-specific antibody dynamics in Seattle, Washington, US, across a broad range of respiratory viruses, including influenza, respiratory syncytial virus, seasonal coronaviruses, and SARS-CoV-2. We found that respiratory virus immunodynamics differed between individuals <5 years of age and older individuals, with young children experiencing both larger boosts and quicker waning of antibodies across pathogens. We confirmed that these patterns are upheld in a non-pandemic setting by analyzing influenza serological data from South Africa. We incorporated our serological insights into an influenza transmission model calibrated to epidemiological data from Seattle and show that consideration of age-specific immunodynamics may be important to anticipate the effects of pandemic perturbations.
Open AccessMultiplex serology reveals age-specific immunodynamics of endemic respiratory pathogens in the wake of the COVID-19 pandemic
The rebound of endemic respiratory viruses following the COVID-19 pandemic was marked by atypical transmission dynamics, with children experiencing increased disease burden and out-of-season epidemics as restrictions relaxed. Here we used serology from a newly developed quantitative multiplex assay to assess the post-pandemic immunity debt, a drop in immunity due to a lack of endemic virus circulation during COVID-19. We assessed age-specific antibody dynamics in Seattle, Washington, US, across a broad range of respiratory viruses, including influenza, respiratory syncytial virus, seasonal coronaviruses, and SARS-CoV-2. We found that respiratory virus immunodynamics differed between individuals <5 years of age and older individuals, with young children experiencing both larger boosts and quicker waning of antibodies across pathogens. We confirmed that these patterns are upheld in a non-pandemic setting by analyzing influenza serological data from South Africa. We incorporated our serological insights into an influenza transmission model calibrated to epidemiological data from Seattle and show that consideration of age-specific immunodynamics may be important to anticipate the effects of pandemic perturbations.
- Open Access
Scenario projections of RSV hospitalizations averted due to new immunization programs in King County, Washington, October 2023 to May 2025
Importance In 2023 new immunization strategies became available for preventing respiratory syncytial virus (RSV)-associated hospitalizations in infants and older adults. Modeling studies to understand the population-level impact of their use are important for public health planning. Objective Estimate the hospitalizations averted in 2023-2024 due to new RSV immunizations and provide scenario projections for future seasons. Design This modeling study used an RSV transmission model calibrated to RSV-diagnosed hospitalizations. Setting King County, WA, October 2023-May 2025 Participants Population of King County, WA (2.3 million individuals), disaggregated into infant, pediatric, adult, and older adult age groups. Exposures RSV vaccination for adults aged ≥60 years, maternal RSV vaccination, and long-acting monoclonal antibodies for infants aged Main Outcomes(s) and Measures(s) Proportion of RSV-diagnosed hospitalizations averted in adults ≥60 years and infants Results Approximately 25% of older adults and 33% of infants benefited from active or passive immunization during the 2023-2024 RSV season. We estimate that 108 (95% PI 89-154) RSV-diagnosed hospitalizations were averted, with most of the benefit observed in infants Conclusions and Relevance Our results suggest a modest reduction in RSV-diagnosed hospitalizations during the 2023-2024 season due to limited availability of immunization products, particularly for infants. We project that higher uptake earlier in the season will lead to substantial reductions in RSV hospitalizations in the 2024-2025 season. Question How many respiratory syncytial virus (RSV)-diagnosed hospitalizations were averted in King County, WA during the 2023-2024 season due to new active and passive immunizations and how can we optimize disease reduction strategies in future seasons? Findings We found moderate reductions in RSV hospitalizations during the 2023-2024 season due to modest coverage. With higher levels of coverage earlier in the season more than half of RSV hospitalizations in infants and a quarter of RSV hospitalizations in older adults could be avoided. Meaning RSV immunizations are a powerful tool for preventing hospitalizations. Modeling studies can support public health strategies to optimize immunization coverage.
Open AccessScenario projections of RSV hospitalizations averted due to new immunization programs in King County, Washington, October 2023 to May 2025
Importance In 2023 new immunization strategies became available for preventing respiratory syncytial virus (RSV)-associated hospitalizations in infants and older adults. Modeling studies to understand the population-level impact of their use are important for public health planning. Objective Estimate the hospitalizations averted in 2023-2024 due to new RSV immunizations and provide scenario projections for future seasons. Design This modeling study used an RSV transmission model calibrated to RSV-diagnosed hospitalizations. Setting King County, WA, October 2023-May 2025 Participants Population of King County, WA (2.3 million individuals), disaggregated into infant, pediatric, adult, and older adult age groups. Exposures RSV vaccination for adults aged ≥60 years, maternal RSV vaccination, and long-acting monoclonal antibodies for infants aged Main Outcomes(s) and Measures(s) Proportion of RSV-diagnosed hospitalizations averted in adults ≥60 years and infants Results Approximately 25% of older adults and 33% of infants benefited from active or passive immunization during the 2023-2024 RSV season. We estimate that 108 (95% PI 89-154) RSV-diagnosed hospitalizations were averted, with most of the benefit observed in infants Conclusions and Relevance Our results suggest a modest reduction in RSV-diagnosed hospitalizations during the 2023-2024 season due to limited availability of immunization products, particularly for infants. We project that higher uptake earlier in the season will lead to substantial reductions in RSV hospitalizations in the 2024-2025 season. Question How many respiratory syncytial virus (RSV)-diagnosed hospitalizations were averted in King County, WA during the 2023-2024 season due to new active and passive immunizations and how can we optimize disease reduction strategies in future seasons? Findings We found moderate reductions in RSV hospitalizations during the 2023-2024 season due to modest coverage. With higher levels of coverage earlier in the season more than half of RSV hospitalizations in infants and a quarter of RSV hospitalizations in older adults could be avoided. Meaning RSV immunizations are a powerful tool for preventing hospitalizations. Modeling studies can support public health strategies to optimize immunization coverage.